

BP-50643

Surovatamig- Anti-Human CD19/CD3 Bispecific Antibody

Surovatamig (AZD0486; TNB-486) is a fully human anti-CD19/CD3 IgG4 bispecific antibody. Surovatamig triggers T cell activation, releases cytotoxic granules, and induces T cell-dependent cellular cytotoxicity and tumor cell lysis. Surovatamig can reduce release of pro-inflammatory cytokines including IL-2, IFN γ , TNF. Surovatamig can be used for the research of cancer, such as B cell non-Hodgkin lymphoma.

Product Details	
Species Reactivity	Human
Source	Mammalian Cells
Isotype	Human IgG4 (S228P) kappa
Class	Anti-Human Bispecific antibodies
Type	Recombinant Humanized
Clone	SP34-2/OKT3
Target	Anti-human CD19/CD3
Purity	>99%
Molecular Weight	110.46 kDa
CAS Number	2892667-02-4
Formulation	NA
Storage conditions	Store at -80°C for 2 years. Aliquots should be stored at the same temperature after first use to avoid multiple freeze-thaws.